Nanometer aggregate, preparation method thereof and application of nanometer aggregate in resisting brain glioma

By using a carrier-free self-assembled nanomedicine delivery platform modified with Angiopep-2-targeted peptides, combined with CPUL1 and gemcitabine, the problems of poor targeting and drug resistance in glioma treatment have been solved, achieving efficient and safe treatment of glioma.

CN118987014APending Publication Date: 2024-11-22CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411149781.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing methods for treating gliomas suffer from poor targeting, strong drug resistance, and significant damage to normal brain tissue. Nanoparticle delivery systems also exhibit uneven drug release and inaccurate biodistribution in vivo, leading to unstable treatment effects, significant side effects, and a lack of effective feedback mechanisms.

Method used

We designed a carrier-free self-assembled nanodrug delivery platform modified with Angiopep-2-targeting peptides. By combining CPUL1 and gemcitabine, nanoaggregates are formed through amide bonds and non-covalent interactions to achieve dual targeting of the brain and mitochondria, enhancing drug stability and targeting, providing sustained drug release, and penetrating the blood-brain barrier.

Benefits of technology

This technology enables the production of nanoparticles with high drug loading capacity and uniform particle size, which prolongs the in vivo circulation cycle, improves bioavailability, significantly enhances the therapeutic effect on glioma, reduces toxicity, and provides a safer treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987014A_ABST
    Figure CN118987014A_ABST
Patent Text Reader

Abstract

The invention discloses a nano aggregate as well as a preparation method and application thereof in resisting brain glioma. The nano aggregate is prepared from a coupling compound of CPUL1 (central processing unit 1) and a triphenylphosphine derivative, gemcitabine, DSPE-mPEG2000 (DP) and Ang-DSPE-mPEG2000 (Ang-DP); the preparation method comprises the following steps: coupling CPUL1 and a triphenylphosphine derivative through an amido bond, and respectively dissolving a coupling compound, gemcitabine, DSPE-mPEG2000 and Ang-DSPE-MPEG2000 in an organic solvent to respectively obtain solutions of the coupling compound, the gemcitabine, the DSPE-mPEG2000 and the Ang-DSPE-MPEG2000; the preparation method comprises the following steps: adding deionized water into a coupling compound solution, stirring for the first time to obtain a mixed solution, adding DSPE-mPEG2000 and Ang-DSPE-mPEG2000 solutions into the mixed solution, stirring again, adding a gemcitabine solution, and finally uniformly stirring to obtain the nano aggregate. The nano aggregate disclosed by the invention shows good stability and high drug loading capacity, realizes in-vitro slow release, has excellent blood brain barrier permeability and targeting property, and shows remarkable in-vivo anti-brain glioma activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medicine, and in particular to a nano aggregate and a preparation method and application thereof. Background Art

[0002] Glioma is the most common primary brain tumor caused by cancerous transformation of glial cells in the brain and spinal cord, accounting for more than 50% of primary intracranial tumors. It is characterized by rapid growth, strong invasiveness, easy recurrence after surgery, and high mortality rate. Among all new tumors, gliomas account for 1.4%, and patients who die from gliomas account for 2.4% of all tumor deaths. Currently, common methods for treating brain gliomas include surgical resection, radiotherapy, and chemotherapy. However, these traditional treatments have limited effects on gliomas and are prone to damage normal brain tissue. Glioma has the ability to infiltrate surrounding tissues, and its edges are difficult to determine. This results in traditional treatments being insufficient to produce cure results. In addition, the presence of physical and chemical barriers prevents drugs from reaching the tumor site, making it difficult to obtain successful treatments.

[0003] In our previous study, we used the principle of molecular splicing to design and synthesize a series of novel pyrano[3,2-a]phenazine hybrid molecules, from which we screened and identified a highly active compound, CPUL1, which is a thioredoxin reductase I (TrxR1) inhibitor. However, the hydrophobic properties of this compound limit its accumulation in cells, and there is a problem that it cannot be effectively enriched at the target site.

[0004] Gemcitabine (GTB) is a nucleoside analogue and one of the most effective drugs against cancer cells. It is widely used in the treatment of various tumors. However, due to its lack of selectivity for cancer tissues, poor targeting, and ability to penetrate cancer cells and healthy cells, it has a short half-life and drug resistance. After entering the blood, more than 90% of GTB in the body will be catalyzed by matrix and cell cytidine deaminase (CDA) into inactive metabolites, resulting in rapid failure of GTB. Therefore, repeated administration is required to maintain effective blood drug concentration, which results in a short treatment time and large side effects. At the same time, excessive ROS generation will stimulate the expression of heme oxygenase-1 and inhibit the expression of CDA. Under low CDA expression, the inactivation of GTB is reduced, thereby exerting an excellent therapeutic effect.

[0005] In order to retain the high anti-cancer activity of chemotherapy drugs while reducing their toxic side effects to other parts of the body, chemotherapy drugs are usually used in combination with nanocarrier-assisted drug delivery systems. These nanocarrier-assisted drug delivery systems have established a new type of cancer treatment and have achieved great success in recent years.

[0006] However, the nanocarrier-assisted drug delivery system still has its inevitable shortcomings: for example, the nanocarrier may release drugs unevenly in the body, resulting in unstable drug concentrations at the treatment site, affecting the therapeutic effect. Its biodistribution in the body may be affected by various factors of the body, resulting in the inability of the drug to accurately reach the treatment site, affecting the therapeutic effect. The nanocarrier itself may have toxic side effects on body tissues, leading to adverse reactions and affecting the patient's quality of life. The effect of the entire delivery treatment is difficult to monitor and evaluate, resulting in a lack of effective feedback and adjustment mechanisms in the treatment process. Therefore, the overall therapeutic effect is unknown. Summary of the invention

[0007] The present invention couples CPUL1 with a triphenylphosphine derivative (TPP) through an amidation reaction to synthesize a mitochondrial-targeted phenazine analog CPUL1-TPP (CT). Previous experimental studies have found that CT not only has mitochondrial targeting but can also inhibit tumor growth by inducing excessive reactive oxygen species (ROS) in tumor cells. However, a single drug is prone to drug resistance and drug resistance during the treatment of cancer. Therefore, two or more chemotherapy drugs are used in combination to increase the sensitivity of tumor cells to drugs and exert the systemic effect of drugs, achieving a "1+1>2" therapeutic effect.

[0008] Based on the characteristics of CT that can induce tumor cells to produce excessive ROS and reduce drug resistance, assembling CT and GTB into the same nanodelivery system for combined use is a very promising tumor treatment strategy.

[0009] In order to solve the problems of drug resistance of chemotherapeutic drugs and insufficient targeting ability of blood-brain barrier, the present invention designs and develops a dual-targeted carrier-free self-assembly nano drug delivery platform with brain targeting and mitochondrial targeting modified by Angiopep-2 targeting polypeptide, which can simultaneously deliver GTB and ROS-generating drug CT, and achieve the purpose of synergistic treatment of brain glioma with two drugs. By adopting carrier-free self-assembly, the insoluble active molecule CT in the nanoparticles can be well dispersed in the aqueous solution, and the stability and targeting of GTB are also enhanced, so that the nanoparticles can be stably present in the body circulation, and at the same time, its toxicity in the body is reduced, the drug is slowly released, and the cellular uptake of the drug is enhanced. The whole preparation process is simple and fast, low-cost and suitable for large-scale factory production of enterprises, and it also provides patients with more effective and safer treatment options, providing more possibilities for the application of nanoparticles in the treatment of brain glioma.

[0010] Purpose of the invention: The purpose of the present invention is to provide a nano-aggregate with high drug loading rate and uniform particle size; another purpose of the present invention is to provide a method for preparing the nano-aggregate; another purpose of the present invention is to provide an anti-glioma application of the nano-aggregate.

[0011] A nano-aggregate, comprising a phenazine derivative CPUL1, a triphenylphosphine derivative, gemcitabine, DSPE-mPEG 2000 (DP) and Ang-DSPE-mPEG 2000 (Ang-DP), the nanoaggregate is formed by coupling CPUL1 with triphenylphosphine derivative (TPP) through amide bond, and then interacts with gemcitabine through non-covalent interaction to form the nanoaggregate core, and DSPE-mPEG 2000 and Ang-DSPE-mPEG 2000 Modified on the surface of the nanoaggregate core.

[0012] The nanoaggregate of the present invention comprises CPUL1, triphenylphosphine derivatives, gemcitabine, DSPE-mPEG 2000 (DP) and Ang-DSPE-mPEG 2000 (Ang-DP), the nanoaggregate is composed of CPUL1 coupled with triphenylphosphine derivatives through amide bonds and then non-covalently interacts with gemcitabine, and DSPE-mPEG 2000 and Ang-DSPE-mPEG 2000 It is used for surface modification of nanoparticles and has the functions of self-assembly, mitochondrial targeting and cell imaging. Nanoaggregates can make the poorly soluble active molecule CPUL1 well dispersed in aqueous solution, and can also enhance the stability of gemcitabine to achieve a good sustained-release drug effect. TPP enables nanoaggregates to aggregate faster and more in the mitochondria of tumor cells, and can release more effective drug molecules faster at the lesion site. DP can maintain the stability of nanoparticles, and Ang-DP can load drugs to efficiently penetrate the blood-brain barrier, thereby achieving the synergistic anti-cancer effect of the two drugs.

[0013] Furthermore, the molar ratio of CPUL1 to the triphenylphosphine derivative is 1:1.

[0014] Furthermore, the molar ratio of the coupling product of CPUL1 and the triphenylphosphine derivative to gemcitabine is 1:1-1:3.

[0015] Furthermore, DSPE-mPEG 2000 and Ang-DSPE-mPEG 2000 The molar ratio is 4:1.

[0016] Furthermore, the coupling product of CPUL1 and triphenylphosphine derivatives was stained with DSPE-mPEG 2000 The molar ratio is 1:0.1-1:0.5.

[0017] Furthermore, the nano-aggregates are in a compact spherical morphology, and the particle size of the nano-aggregates is 100nm-200nm.

[0018] A second object of the present invention is to provide a method for preparing the aforementioned nano-aggregates, comprising the following steps:

[0019] (1) CPUL1 and a triphenylphosphine derivative were coupled via an amide bond to synthesize the compound CPUL1-TPP;

[0020] Specifically, the amino group in CPUL1 is coupled with a carboxyl-containing mitochondrial targeting ligand triphenylphosphine derivative (TPP) through an amide bond to synthesize the compound CPUL1-TPP.

[0021] (2) CPUL1-TPP, gemcitabine, DSPE-mPEG 2000 and Ang-DSPE-mPEG 2000 Dissolved in solvents respectively to obtain CPUL1-TPP solution, gemcitabine solution, DSPE-mPEG 2000 Solution and Ang-DSPE-mPEG 2000 Solution; or, the DSPE-mPEG 2000 and Ang-DSPE-mPEG 2000 After mixing, it was dissolved in an organic solvent to obtain DSPE-mPEG 2000 and Ang-DSPE-mPEG 2000 A mixed solution;

[0022] (3) Deionized water was added to the CPUL1-TPP solution, and the mixture was initially stirred to obtain a mixed solution. DSPE-mPEG was added to the mixed solution. 2000 Solution and Ang-DSPE-mPEG 2000 Solution, or, adding DSPE-mPEG to the mixed solution 2000 and Ang-DSPE-mPEG 2000 after stirring again, gemcitabine solution was added, and finally the mixture was stirred evenly to obtain nano-aggregates.

[0023] Furthermore, in step (2), the solvent is water or an organic solvent;

[0024] Preferably, the organic solvent is any one of ethyl acetate, acetone, methanol, dichloromethane, chloroform, ethyl propionate, propyl acetate, dimethyl sulfoxide or ethanol.

[0025] Furthermore, in step (3), the initial stirring, the secondary stirring and / or the final stirring are magnetic stirring.

[0026] Furthermore, in step (3), the temperature of the first stirring, the second stirring and / or the final stirring is 20-60° C., the stirring speed is 50-1000 rpm, and the stirring time is 0.5-3 h.

[0027] The third object of the present invention is to provide the use of the aforementioned nano-aggregates in the preparation of anti-glioma drugs.

[0028] The nano-aggregates of the present invention have a particle size of nanometers, which can prolong the in vivo circulation period. The nano-particles have a small particle size, have a good EPR effect, and are easy to accumulate at the tumor site.

[0029] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages:

[0030] (1) Nanoaggregates have a high drug loading rate and do not contain other carrier materials, thus avoiding the problem of low drug loading rate requiring large-scale injection and the additional toxicity that may be caused by carrier materials;

[0031] (2) The nanoaggregates have uniform particle size, which can effectively prolong the drug's in vivo circulation cycle, improve bioavailability, and are easily enriched in tumor sites through the EPR effect;

[0032] (3) The nanoaggregates have excellent blood-brain barrier permeability and targeting properties, and exhibit significant anti-glioma activity in vivo. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 The hydrated particle size distribution (A) and transmission electron microscopy image (B) of the nanoaggregates in Example 1;

[0034] Figure 2 is the zeta potential distribution diagram of the nanoaggregates in Example 1, wherein: Figure 2 A is the zeta potential distribution diagram of nanoaggregates with a CT:GTB molar ratio of 1:1. Figure 2 B is the zeta potential distribution diagram of nanoaggregates with a CT:GTB molar ratio of 1:2. Figure 2 C is the zeta potential distribution diagram of nanoaggregates with a CT:GTB molar ratio of 1:3;

[0035] Figure 3 is the stability of the nanoaggregates in Example 1, and the data are expressed as mean ± SD (n = 3);

[0036] Figure 4 is the drug release curve of the drug in the nanoaggregate at different pH in vitro in Example 2, wherein, Figure 4 Drug A is GTB, Figure 4 Drug B is CT;

[0037] Figure 5The graph is a result of the killing effect of different concentrations of samples CT, GTB, CT / GTB NAs, DP@CT / GTB and Ang-DP@CT / GTB on U87 cells in Example 3;

[0038] Figure 6 This is a graph showing the ability of different concentrations of samples CPUL1, CT, GTB and Ang-DP@CT / GTB NAs to generate superoxide in U87 cells in Example 4;

[0039] Figure 7 The images of mitochondrial localization of DP@CT / GTB NAs in U87 cells at different time points detected by laser confocal microscopy in Example 5;

[0040] Figure 8 This is a data compilation chart of tumor levels, weight changes, and median survival time of mice after treatment in Example 6, where: Figure 8 A is a statistical chart showing the average changes in the bioluminescence level of mouse GL261-luc tumors; Figure 8 B is a statistical chart showing the changes in the average weight of mice; Figure 8 C is a statistical graph of the median survival time of mice;

[0041] Fig. 9 This is a bioluminescent imaging image of GBM tumor growth in mice after drug administration in Example 6. DETAILED DESCRIPTION

[0042] The present invention is further explained below with reference to the examples, but the examples do not limit the present invention in any form.

[0043] Example 1: Preparation and characterization of Ang-DP@CT / GTB NAs and DP@CT / GTB NAs

[0044] The nanoaggregates provided in this embodiment include CPUL1, TPP, GTB, DSPE-PEG 2000 and Ang-DSPE-mPEG 2000 , the preparation method is as follows:

[0045] (1) Weigh 1 g (2.3 mmol) of CPUL1, 1.02 g (2.3 mmol) of TPP, 0.66 g (3.45 mmol) of EDCI, 0.47 g (3.45 mmol) of HOBt and 0.98 g (7.59 mmol) of DIPEA; dissolve TPP, EDCI and HOBt in 4 mL of DMF, under nitrogen protection, and stir thoroughly in an ice bath for 1 h; then dissolve CPUL1 and DIPEA in 6 mL of DMF, add to the reaction system, and stir the reaction at room temperature; during the reaction, take samples every 4-6 h, compare with TLC spots, and monitor the reaction conditions; after stopping the reaction, extract and remove the solvent DMF. Extraction method: use dichloromethane (DCM) as the organic phase, extract with 180 mL of pure water 3 times, 60 mL of saturated NaCl solution 2 times, and 60 mL of saturated NaHCO3 solution 2 times, collect the organic phase and spin dry; Purification: Use silica gel column adsorption chromatography to purify the crude product with a developing solvent ratio of MT:DCM=1:15, ethyl acetate beating purification, etc., and dry in a vacuum oven to obtain the product CPUL1-TPP (CT).

[0046] (2) Weigh 300 mg of phospholipid polyethylene glycol maleimide DSPE-PEG 2000 -MAL was dissolved in 10 ml DMF, and Angiopep-2-Cys peptide (1.1 eq.) was added and dissolved completely, and the reaction was stirred at room temperature for 12 h; the reaction solution was transferred to a dialysis bag (molecular weight cutoff 3000 Da) for 48 h, and dialyzed in pure water for 24 h. The dialyzate was collected and freeze-dried and further purified to obtain a white flocculent solid. The freeze-dried product Ang-DSPE-PEG was purified using TLC tracer molecular sieve. 2000 (Ang-DP), that is, the Ang-DSPE-mPEG required for preparing nanoaggregates was prepared 2000 (Ang-DP);

[0047] (3) 4.285 mg (5 μmol) of CPUL1-TPP was dissolved in 100 μL of dimethyl sulfoxide to obtain a solution A with a CPUL1-TPP molar concentration of 60 mmol / L;

[0048] 1.315 mg (5 μmol) of gemcitabine (GTB) was dissolved in 100 μL of dimethyl sulfoxide to obtain a solution B with a molar concentration of GTB of 60 mmol / L;

[0049] 2.5 mg of DP (1.25 μmol) was dissolved in 100 μL of dimethyl sulfoxide to obtain solution C.

[0050] 1.1 mg Ang-DP (0.25 μmol) was dissolved in 500 μL ultrapure water to obtain solution D;

[0051] (5) 100 μL of solution A was injected into 4.7 mL of deionized water and magnetically stirred at 650 rpm at 25 °C. 100 μL of solution B was injected into the system at a speed of 2 μL / s to mix. Then 100 μL of solution C was injected into the mixed system at 2 μL / s and magnetically stirred at 650 rpm at 25 °C for 0.5 h to obtain nanoaggregates DP@CT / GTB NAs with a CT:GTB molar ratio of 1:1.

[0052] (6) The amount of CPUL1-TPP(CT) was kept unchanged and nanoaggregates with other molar ratios (1:2, 1:3) were prepared by adjusting the amount of GTB.

[0053] (7) 100 μL of solution A was injected into 4.72 mL of deionized water and magnetically stirred at 650 rpm at 25 °C. 100 μL of solution B was injected into the system at a speed of 2 μL / s for mixing. Then 80 μL of solution C was injected into the mixed system at 2 μL / s. Finally, 500 μL of solution D was injected into the mixed system at 2 μL / s. The mixture was magnetically stirred at 650 rpm at 25 °C for 1.5 h to obtain nanoaggregates Ang-DP@CT / GTB NAs with a CT:GTB molar ratio of 1:1, a DP to Ang-DP molar ratio of 4:1, and a CT to DP molar ratio of 1:0.2.

[0054] Ang-DP@CT / GTB NAs is a nanostructured NA prepared by adding an Ang peptide target head to DP@CT / GTB NAs, which improves the blood-brain barrier permeability of the nanoaggregates. However, other physical and chemical properties remain unchanged. Therefore, some subsequent experiments used DP@CT / GTB NAs prepared in steps (5) and (6) instead of Ang-DP@CT / GTB NAs for testing.

[0055] Dynamic light scattering (DLS) was used to study the size and size distribution of nanoaggregates with different molar ratios of CT to GTB, e.g. Figure 1 As shown, the particle size distribution of nano-aggregates in different proportions is uniform, mainly distributed in the range of 100nm-200nm.

[0056] Electrophoretic light scattering (ELS) was used to measure the zeta potential of nanoaggregates at different ratios. Figure 2 As shown, the potentials of the nanoaggregates with three CPUL1-TPP and GTB ratios all float around zero, approaching electrical neutrality.

[0057] Among them, the particle size performance was the best when the molar ratio of CT to GTB was 1:2, so it was used for testing in subsequent experiments.

[0058] like Figure 3 As shown, DP@CT / GTB NAs exhibited good stability within 10 days at a temperature of 25 °C and a molar ratio of CT to GTB of 1:2.

[0059] Example 2: In vitro drug release of Ang-DP@CT / GTB NAs

[0060] The in vitro drug release of nanoaggregates in PBS at different pH conditions was determined by HPLC as follows:

[0061] (1) Draw a standard curve: weigh 10 mg of gemcitabine into a 10 mL volumetric flask, add methanol to make up the volume, shake well to prepare a standard solution for use, and then dilute with methanol to 0.01 mg / mL, 0.02 mg / mL, 0.03 mg / mL, 0.04 mg / mL, 0.06 mg / mL, and 0.1 mg / mL; number of injections: repeat the injection three times at the same concentration. Draw a standard curve with the peak area as the ordinate and the concentration as the abscissa. (The pH of the PBS used was 5.8 and 7.4; instrument parameters: chromatographic column: SB-C-18 reverse chromatographic column, 250 mm-4.6 mm (id), stainless steel column; mobile phase: acetonitrile and water volume ratio of 20:80; flow rate: 1 mL / min; detection wavelength: 275 nm; injection volume: 1 mL; column temperature: 25 °C)

[0062] (2) Determine the drug release of nanoaggregates when the molar ratio of CT to GTB is 1:2. Place the nanoaggregates in PBS and stir continuously for 48 hours. Take samples every 1-3 hours for testing. Each sampling point is tested three times and the average value is taken. The drug release rate (Q%) is calculated according to the following formula:

[0063]

[0064] In the formula, C n is the CT or GTB concentration at the nth sampling point, V is the volume of the release medium, C i is the CT or GTB concentration at the i-th sampling point, V i is the volume of the sample taken at the i-th sampling point, and M is the total mass of CT or GTB in the nanoaggregates.

[0065] Since the rapid growth of tumors in the body requires a large amount of nutrients, tumor cells will simultaneously activate multiple energy supply pathways. During the rapid energy metabolism, a large amount of phosphate will be produced, which puts the tumor in a slightly acidic environment (pH = 5.8), which is quite different from the surrounding normal cell environment (pH = 7.4).

[0066] Therefore, this experiment set up two different drug release systems (phosphate buffer solution with pH = 5.8 and phosphate buffer solution with pH = 5.8) to simulate the drug release behavior in tumor microenvironment and normal cells, and to determine the effect of pH on drug release. Figure 4 As shown in the graph, in the phosphate buffer solution system with pH = 5.8, the cumulative release of GTB in about 12 hours is about 40%, which is higher than the 30% cumulative release in the phosphate buffer solution system with pH = 7.4, indicating that the acidic tumor microenvironment can make the chemotherapy drug GTB released faster ( Figure 4 A), the release results of compound CT in pH = 5.8 or pH = 7.4 system are similar to the release effect of GTB ( Figure 4 B), indicating that nanoparticles can release more drugs in tumor tissue cells and are more toxic to tumor cells than normal cells.

[0067] Example 3: Cytotoxicity evaluation of Ang-DP@CT / GTB NAs

[0068] The cytotoxicity of CPUL1-TPP, GTB and Ang-DP@CT / GTBNAs was determined by MTT colorimetric assay on U87 cells as follows:

[0069] (1) Cell culture: U87 cells were cultured in DMEM medium (containing 10% fetal bovine serum and 1% penicillin / streptomycin) in an incubator at 37° C. and 5% carbon dioxide.

[0070] (2) Cell viability assay: Sample solutions of CT, GTB, CT / GTB NAs, DP@CT / GTB, and Ang-DP@CT / GTB with different concentrations were set as the experimental group; sample solutions containing the same concentration of DMSO were set as the control group; and complete culture medium without cells was set as the blank group. Different compounds and nanoparticle stock solutions were diluted according to the concentration gradient, and the concentrations were set to 10μM, 5μM, 2.5μM, 1.25μM, 0.625μM, and 0.3125μM for drug treatment. Six replicates were set in each well, and three parallel groups were set for each concentration in each group. After drug treatment, the cells were cultured for another 48h. After 48h of culture, 10μL of MTT (5.0mg / mL) was added. After incubation for 4h, the culture medium was removed and 150μL of dimethyl sulfoxide was added to dissolve the purple crystals. The absorbance of the solution at 490nm was measured using a multifunctional microplate reader. Cells cultured without any treatment were used as the control. Three parallel wells were set in each group.

[0071] like Figure 5As shown, the cytotoxic effect of free GTB varies greatly at low concentrations. As the drug concentration increases, the cytotoxic effect of GTB does not change significantly, and the cytotoxic effect of other groups is significantly enhanced. The inhibition rate of tumor cells in the combined drug CT / GTB group and the nanodrug group is significantly higher than that of free drugs CT and GTB, which has a synergistic effect, proving that the combination of CT and GTB can better inhibit the growth and proliferation of tumor cells. At the same time, the cytotoxicity of NAs with different molar ratios was tested, but there was no significant difference in the IC50 values. This shows that the self-assembled nanoaggregates prepared by this method can achieve better tumor inhibition effects at lower drug concentrations.

[0072] Example 4: Intracellular superoxide generation ability of Ang-DP@CT / GTB NAs

[0073] The ability of U87 cells to produce superoxide when co-incubated with samples was observed using an inverted fluorescence microscope, and the superoxide produced when U87 cells were co-incubated with samples was quantitatively analyzed using a flow cytometer. The specific steps are as follows:

[0074] (1) Select U87 cells that are in good growth condition and in the logarithmic growth phase, digest with trypsin, centrifuge, mix and resuspend, and count the cells. Place the cells at 2.5×10 per well. 5 The cells were seeded into 12-well plates at a density of 100 and incubated in an incubator at 37°C with 5% CO2.

[0075] (2) After incubation for about 24 h until the cells were completely unattached, sample solutions of CPUL1, CT, GTB, and Ang-DP@CT / GTB NAs at concentrations of 10 μM, 5 μM, and 2.5 μM were added for treatment, with three replicate wells set up for each group.

[0076] (3) After incubation for 12 h, discard the old culture medium, wash twice with preheated PBS, and add 200 μL MitoSOX to each well. TM Red staining working solution (5 μM), stain at 37°C in the dark for 10 min, discard the staining solution, and wash three times with preheated PBS.

[0077] (4) After step (3) incubation, if the ability of U87 cells to produce superoxide when co-incubated with the sample is to be observed, the following steps are required: add 400 μL of 4% paraformaldehyde to each well and incubate for 20 min, then discard the fixative, wash three times with PBS, add 200 μL of DAPI for staining for 10 min, and then wash three times with PBS. Take out the coverslip, place it on a slide with an anti-quencher, drip the sealing solution around the coverslip, observe with an inverted fluorescence microscope and take photos.

[0078] (5) After step (4) is completed, if the superoxide produced by co-incubation of U87 cells with samples is to be quantitatively analyzed, the following steps are required: add 200 μL of EDTA-free trypsin (TP) to each well for digestion for 1 min, add 500 μL of culture medium to neutralize TP and blow the cells until they fall off, collect the cells into a 1.5 mL EP tube, and centrifuge (400 g) for 5 min. After centrifugation, discard the supernatant, add PBS to wash the cells, resuspend them, and centrifuge again. Repeat the washing twice, discard the supernatant, add 500 μL PBS to each EP tube, blow and suspend them, filter the cells with a 400-mesh cell sieve, and then use a flow cytometer to quantitatively detect the changes in intracellular ROS.

[0079] like Figure 6 As shown, Ang-DP@CT / GTB NAs induced the generation of ROS in a dose-dependent manner. The mitochondria of cells treated with Ang-DP@CT / GTB NAs showed stronger red fluorescence, and MitoSOX Red was oxidized by superoxide. Compared with free CPUL1, CT, and GTB, the superoxide content in mitochondria increased significantly after cells were incubated with the same concentration of Ang-DP@CT / GTB NAs for 24 h, leading to superoxide accumulation and mitochondrial membrane damage.

[0080] Example 5: Mitochondrial targeting of DP@CT / GTB NAs

[0081] In this example, the targeting effect of the DP@CT / GTB NAs prepared in step (5) of Example 1 on the mitochondria of U87 cells was tested as follows:

[0082] (1) Cell culture: U87 cells were cultured in DMEM containing 10% fetal bovine serum and 1% penicillin / streptomycin in an incubator at 37° C. and 5% carbon dioxide.

[0083] (2) Observation of nanoaggregates targeting mitochondria: U87 cells in good condition in step (1) were selected and 1×10 5The cells were seeded at a density of 100 cells / well in a 24-well plate covered with a cover glass, placed in a 5% CO2 incubator, and cultured at 37°C for 24 hours to allow the cells to fully adhere to the wall. The cells were treated with a sample solution of DP@CT / GTB NAs at a concentration of 2.5μM and incubated at 37°C for 1h and 4h. After the addition of drugs, the culture medium was discarded, and the cells were washed twice with PBS buffer solution. The mitochondrial red fluorescent probe MitoTracker Red (100nM) was added to stain U87 cells in the dark for 30min. They were fixed with 4% paraformaldehyde (PFA) for 20min, and finally washed twice with PBS buffer solution to remove excess PFA. The cover glass was removed and placed on a slide with an antifade agent. The sealing solution was dripped around the cover glass, and the localization of mitochondria in the cell was detected by laser confocal microscopy (CLSM). The green fluorescence of CPUL1 itself overlapped with the red fluorescence of the dye to produce yellow fluorescence. The degree of mitochondrial colocalization was expressed by the Pearson correlation coefficient.

[0084] like Figure 7 As shown in the figure, in U87 cells, DP@CT / GTB NAs can co-localize with the dye in mitochondria after incubation for 1h or 4h. In addition, the co-localization fluorescence intensity of the nanoaggregates decreased significantly over time. This may be because the nanoaggregates caused the accumulation of superoxide in the cells, resulting in damage to the mitochondrial membrane and partial escape of CT from the mitochondria into the cytoplasm.

[0085] Example 6: Ang-DP@CT / GTB NAs treatment of GBM model in mice

[0086] Establish a GBM tumor model in mice, compare the treated mice, and observe the growth of brain glioma in the treated mice by bioluminescence imaging. The specific steps are as follows:

[0087] (1) The gl261-luc cells grown in the culture medium were digested with TP and washed twice with PBS. After diluting with 100 μL of PBS, they were used for injection. After anesthetizing the mouse with 360 μL of abdominal anesthesia (injected with a 1 ml syringe in the lower abdomen), the hair on the mouse's head was removed with a depilatory cream. The mouse's mouth, nose and two teeth were fixed with a stereotaxic instrument. The mouse's scalp was cut open longitudinally with forceps and scissors. A "cross" was found on the mouse's head. The injection needle was aimed at the "cross" part. The instrument's x-axis was adjusted to "-1.5", the y-axis to "-3", and the z-axis was adjusted to the mouse's scalp and the value was reset to zero. The injection needle was inserted into the mouse's skull until the z-axis was adjusted to "-3.5". After waiting for 15 seconds, the needle was pulled out along the z-axis to "0.5" and then 10 μL of cell dilution was slowly injected. After the injection was completed, wait for a few seconds and pull out the needle within 3 minutes. The wound was sutured, disinfected with iodine first and then sutured. The mouse was placed on an electric blanket and returned to the cage after it woke up.

[0088] (2) After waiting for six days for the GBM tumors in the mice to grow to a certain size, the mice were evenly divided into groups according to their weight and divided into PBS, Free CT, Free GTB, DP@CT / GTB NAs and Ang-DP@CT / GTB NAs treatments. Starting from the sixth day, the drugs were injected into the tail vein of the mice every two days (days 6, 8, 10, 12, and 14). The growth of GBM tumors in the mice and the changes in the weight of the mice were recorded by bioluminescence imaging every two days (days 6, 8, 10, 12, 14, and 16). Finally, the mice were cultured after the drug administration was stopped, and the median survival time of the mice was recorded.

[0089] Finally, the recorded data was sorted out, and the results were as follows Figure 8 As shown in the figure, after the mice in the Ang-DP@CT / GTB NAs group received drug treatment, the average bioluminescence level of the mouse GL261-luc tumor was significantly lower than that of the other groups, the body weight was maintained at a relatively stable level, and the median survival time was the longest. This shows that compared with other groups, Ang-DP@CT / GTB NAs not only has the best therapeutic effect in treating GBM tumors in mice, but also has the lowest cytotoxicity. Fig. 9 Bioluminescence imaging also clearly shows the growth of GBM tumors in treated mice. Ang-DP@CT / GTB NAs is the most effective in inhibiting mouse tumor growth. In summary, Ang-DP@CT / GTB NAs not only has the best therapeutic effect in treating mice, but can also effectively inhibit the growth of GBM tumor cells in mice. It also has the least cytotoxicity in mice and the least damage to mouse growth and survival.

[0090] In summary, the Ang-DP@CT / GTB NAs nanoaggregates in the present invention have good stability, high drug loading and great biosafety potential. The synergistic modification of nanoaggregates by multiple drugs can make the poorly soluble active molecule CPUL1 well dispersed in aqueous solution, and also enhance the stability and targeting of gemcitabine, thereby achieving the synergistic anti-glioma effect of the two drugs. The present invention will provide new opportunities for personalized treatment and diagnosis of multiple drug synergistic self-assembly, self-release drugs and cell imaging systems.

[0091] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A nano-aggregate, characterized in that: The nano-aggregates include phenazine derivatives CPUL1, triphenylphosphine derivatives, gemcitabine, DSPE-mPEG 2000 and Ang-DSPE-mPEG 2000 The nanoaggregates were formed by coupling CPUL1 with triphenylphosphine derivatives through amide bonds, and then interacting with gemcitabine through non-covalent interactions to form the nanoaggregate core. 2000 and Ang-DSPE-mPEG 2000 Modified on the surface of the nanoaggregate core.

2. The nanoaggregate according to claim 1, characterized in that The molar ratio of CPUL1 to the triphenylphosphine derivative was 1:

1.

3. The nanoaggregate according to claim 1, characterized in that The molar ratio of the coupling product of CPUL1 and the triphenylphosphine derivative to gemcitabine is 1:1-1:

3.

4. The nanoaggregate according to claim 1, characterized in that DSPE-mPEG 2000 and Ang-DSPE-mPEG 2000 The molar ratio is 4:

1.

5. The nanoaggregate according to claim 1, characterized in that Coupling products of CPUL1 and triphenylphosphine derivatives with DSPE-mPEG 2000 The molar ratio is 1:0.1-1:0.

5.

6. The nanoaggregate according to claim 1, characterized in that The nano aggregates are in a compact spherical shape, and the particle size of the nano aggregates is 100nm-200nm.

7. The method for preparing nano-aggregates according to any one of claims 1 to 6, characterized in that: The following steps are involved: (1) CPUL1 and a triphenylphosphine derivative were coupled via an amide bond to synthesize the compound CPUL1-TPP; (2) CPUL1-TPP, gemcitabine, DSPE-mPEG 2000 and Ang-DSPE-mPEG 2000 Dissolved in solvents respectively to obtain CPUL1-TPP solution, gemcitabine solution, DSPE-mPEG 2000 Solution and Ang-DSPE-mPEG 2000 Solution; or, the DSPE-mPEG 2000 and Ang-DSPE-mPEG 2000 After mixing, it was dissolved in an organic solvent to obtain DSPE-mPEG 2000 and Ang-DSPE-mPEG 2000 A mixed solution; (3) Deionized water was added to the CPUL1-TPP solution, and gemcitabine solution was added after initial stirring, and the mixture was stirred again to obtain a mixed solution of the two, and DSPE-mPEG was then added to the mixed solution. 2000 Solution and Ang-DSPE-mPEG 2000 Solution, or, adding DSPE-mPEG to the mixed solution 2000 and Ang-DSPE-mPEG 2000 A mixed solution; Finally, the nano-aggregates are obtained by stirring evenly.

8. The preparation method according to claim 7, characterized in that: In step (2), the solvent is water or an organic solvent; preferably, the organic solvent is any one of ethyl acetate, acetone, methanol, dichloromethane, chloroform, ethyl propionate, propyl acetate, dimethyl sulfoxide or ethanol.

9. The preparation method according to claim 7, characterized in that: In step (3), the temperature of the first stirring, the second stirring and / or the final stirring is 20-60° C., the stirring speed is 50-1000 rpm, and the stirring time is 0.5-3 h.

10. Use of the nanoaggregate according to any one of claims 1 to 6 in the preparation of anti-glioma drugs.